Clinical trials: Locally Advanced Pancreatic Carcinoma
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Pancreatic Neoplasm
CROSSFIRE Trial: Comparing the Efficacy of Irreversible Electroporation With Radiotherapy
Irreversible electroporation (IRE) is a promising new ablation technique to fight pancreatic cancer. The primary aim of the CROSSFIRE trial is to compare the efficacy (in terms of overall survival) of FOLFIRINOX and IRE…
- Trial name
- CROSSFIRE (NCT02791503)
- Testing
- Irreversible electroporation (IRE), Stereotactic ablative radiotherapy (SABR)
- Where
- Netherlands
- Volunteers
- 74 people
- Sponsor
- Dr. M.R. Meijerink
Pancreatic Ductal Adenocarcinoma, Pancreas Adenocarcinoma
Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)
A Phase II Open-Label Study of Enfortumab Vedotin in Patients with Previously Treated Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma (EPIC)
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreas Adenocarcinoma, Pancreas Cancer
- Trial name
- NCT05915351
- Testing
- Enfortumab vedotin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Kansas Medical Center
Pancreatic Carcinoma Non-resectable, Metastatic Pancreatic Cancer
Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer
People with pancreatic cancer usually have a large amount of the cancer in the area of the pancreas and around it when they are diagnosed with it.
- Trial name
- NCT00761345
- Testing
- gemcitabine, Erlotinib, low dose fractionated radiotherapy
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Fox Chase Cancer Center
Pancreatic Cancer Non-resectable
Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer
This phase-2 monocenter non-randomized prospective clinical trial evaluates the effectiveness of minimally invasive microwave ablation plus immunotherapy for unresectable non-metastatic locally advanced pancreatic cancer.
- Trial name
- MIMIPAC (NCT04156087)
- Testing
- Durvalumab 50 MG/ML, Tremelimumab, Gemcitabine
- Where
- Belgium
- Volunteers
- 12 people
- Sponsor
- Baki Topal
Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer
The purpose of this study is to determine the safety and tolerability of three intratumoral injections of VCN-01 combined with Abraxane®/gemcitabine, and to determine the recommended phase II dose of VCN-01 combined with…
- Trial name
- NCT02045589
- Testing
- VCN-01, Gemcitabine, Abraxane®
- Where
- 3 sites in Spain
- Volunteers
- 8 people
- Sponsor
- Theriva Biologics SL
Pancreatic Cancer
Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00425360
- Testing
- sargramostim, telomerase peptide vaccine GV1001, capecitabine
- Where
- 45 sites in United Kingdom
- Volunteers
- 1,110 people
- Sponsor
- Royal Liverpool University Hospital
Pancreatic Cancer
Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer
The prognosis of pancreatic cancer is extremely poor. Current guidelines recommend FOLFIRINOX or modified-FOLFIRINOX as the first-line chemotherapeutic regimen.
- Trial name
- NCT03983057
- Testing
- Anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 392 people
- Sponsor
- Zhejiang University
Pancreatic Cancer, Adult
QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
This was a Phase 1/2 multi-institution prospective open label study in which subjects with metastatic, locally advanced unresectable or recurrent pancreatic cancer who previously received treatment with chemotherapy with…
- Trial name
- NCT01834235
- Testing
- Gemcitabine, nab-paclitaxel, NPC-1C
- Where
- 12 sites in United States
- Volunteers
- 81 people
- Sponsor
- Precision Biologics, Inc
Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC)
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
This is a global, multi-center, open-label, Phase I/II first-in-human study of XNW27011 monotherapy as an investigational product (IP) in patients with locally advanced and/or metastatic solid tumors who have failed or are…
- Conditions
- Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic
- Trial name
- NCT06792435
- Testing
- XNW27011
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
This phase II trial is studying how well triapine works as first-line or second-line therapy in treating patients with locally advanced or metastatic adenocarcinoma (cancer) of the pancreas.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00085371
- Testing
- triapine
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer Non-resectable, Brachytherapy
I125 Seed Implantation vs Stereotactic Radiotherapy for Pancreatic Cancer
Data of 100 patients with locally advanced pancreatic cancer who received stereotactic radiotherapy or ct-guided radioactive 125I seed implantation in the multicenter of the research group from July 2019 to June 2021 were…
- Conditions
- Pancreatic Cancer Non-resectable, Brachytherapy, Radiotherapy
- Trial name
- Ckvssip (NCT03964064)
- Testing
- Stereotactic Radiotherapy, 3D-printing Template-assisted CT-guided I125 Seed Implantation
- Where
- 4 sites in China
- Volunteers
- 100 people
- Sponsor
- Peking University Third Hospital
Pancreatic Cancer
Ablation of Unresectable Locally Advanced Pancreatic Cancer With Irreversible Electroporation (IRE) System
Patients with pancreatic ductal adenocarcinoma will be screened by pancreatic protocol cross-sectional imaging to see if they have locally advanced unresectable pancreatic ductal adenocarcinoma.
- Trial name
- NCT03614910
- Testing
- Nanoknife Irreversible Electroporation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Holy Name Medical Center, Inc.
Pancreatic Cancer
Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00281996
- Testing
- Gemcitabine, Imatinib mesylate
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Northwestern University
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer
This phase I trial studies the side effects of losartan and hypofractionated radiation therapy after chemotherapy in treating patients with pancreatic cancer that may or may not be removed by surgery (borderline resectable) or…
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Locally Advanced Unresectable Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8
- Trial name
- SHAPER (NCT04106856)
- Testing
- Hypofractionated Radiation Therapy, Losartan, Losartan Potassium
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Utah
Pancreatic Cancer
Locally Advanced Pancreatic Cancer Treated With ABLAtivE Stereotactic MRI-guided Adaptive Radiation Therapy
Ablative dose magnetic resonance imaging (MRI) guided hypofractionated radiation therapy delivered using daily adaptive dose planning has shown to improve overall survival, relative to patients receiving lower radiation doses, in…
- Trial name
- LAP-ABLATE (NCT05585554)
- Testing
- MRIdian
- Volunteers
- 267 people
- Sponsor
- Viewray Inc.
Pancreatic Cancer
Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy
This randomized trial examines the effectiveness of chemoradiotherapy compared to chemotherapy alone after induction chemotherapy with 3 cycles of gemcitabine or 6 cycles of FOLFIRINOX in patients with locally advanced, non…
- Trial name
- CONKO-007 (NCT01827553)
- Testing
- Induction chemotherapy with gemcitabine or FOLFIRINOX, Radiotherapy, 28 x 1.8 Gy, Chemotherapy, gemcitabine
- Where
- 23 sites in Germany
- Volunteers
- 830 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Pancreatic Cancer
Iodine-125 Seed Implantation Therapy for Locally Advanced Pancreatic Cancer
This study evaluates the application of 3D-printed template for iodine-125 seed implantation therapy in patients with locally advanced pancreatic cancer.
- Trial name
- NCT03882866
- Testing
- 3D-printed non-coplanar template, 3D-printed coplanar template
- Where
- 8 sites in China
- Volunteers
- 220 people
- Sponsor
- Ruijin Hospital
Treatment
Different Patterns of Target Delineation in SBRT for Locally Advanced Pancreatic Cancer
The purpose of this study is to compare the efficacy and safety of a recurrence-pattern-based-volume versus conventional-volume stereotactic body radiation therapy for locally advanced pancreatic cancer, so as to determine…
- Trial name
- NCT04699539
- Testing
- SBRT, Chemotherapy
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Changhai Hospital
Locally Advanced Pancreatic Cancer, Irreversible Electroporation
Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer
Background Pancreatic cancer is one the leading causes of cancer-related death in Canada. Approximately 40 percent of patients with pancreatic cancer present with locally advanced pancreatic cancer and are not candidate for…
- Trial name
- SMART (NCT04276857)
- Testing
- Irreversible electroporation (NanoKnife® )
- Where
- 2 sites in Canada
- Volunteers
- 27 people
- Sponsor
- University of Saskatchewan